Compare BRCB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | BNR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | China |
| Employees | 2800 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.8M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | BRCB | BNR |
|---|---|---|
| Price | $12.26 | $16.00 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $26.83 | N/A |
| AVG Volume (30 Days) | ★ 615.2K | 26.3K |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.77 | $111.65 |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $2.18 |
| 52 Week High | $30.40 | $41.72 |
| Indicator | BRCB | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 31.47 | 35.27 |
| Support Level | $11.51 | $15.52 |
| Resistance Level | $17.60 | $24.23 |
| Average True Range (ATR) | 1.10 | 1.77 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 5.46 | 10.78 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.